Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01895842
Recruitment Status : Completed
First Posted : July 11, 2013
Last Update Posted : April 16, 2019
Incyte Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center